Brickell Biotech prepares $50M at-the-market offering to fund company through Phase III trials

BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) is preparing to sell up to $50 million in new stock sales to fund it through two pivotal Phase III trials for its flagship drug. 

The Boulder pharmaceutical company posted revenues of just $27,000 in the final quarter of 2020 from royalties garnered from sales of its co-developed overactive underarm-sweating treatment in Japan. It also posted a net loss of $7.4 million for the quarter.

For all of 2020, the company had revenues of $1.8 million, mostly from collaboration fees paid out by its Japanese development partner Kaken Pharmaceutical Co. Ltd. Its total loss for the year was $20.9 million.

SPONSORED CONTENT

Prioritizing mental health in hospice care

Prioritizing mental health support alongside physical comfort, Pathways hospice care aims to enhance the quality of life for patients and their families during one of life's most challenging transitions.

The company had $30.1 million in cash and equivalents on hand at the end of the year, which it expects will sustain it through two Phase III studies of its anti-sweating treatment. Those studies are expected to produce top-line data in the final quarter of 2021, potentially setting up the treatment to go in front of federal drug regulators for commercial approval next year.

In a separate filing with the U.S. Securities and Exchange Commission, Brickell said it had reached an agreement with two investment banks to sell up to $50 million in new stock on demand to investors at market prices. If issued at the company’s opening price of $1.05 per share as of Wednesday morning, it could add just less than 47.62 million to its 66.93 million shares outstanding.